Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Diakonos Oncology

Request full access

Innovative cancer immunotherapies designed to fully harness the power of the immune system

Houston, United StatesFounded 2016Biotech & Life Sciences

About Diakonos Oncology

Diakonos Oncology Corporation is a clinical-stage biotechnology firm focused on developing immunotherapies for aggressive and difficult-to-treat cancers. Founded in 2016 and headquartered in Houston, Texas, the company is built upon research from leading institutions like Baylor College of Medicine. The leadership team includes CEO Mike Wicks, President and COO Jay Hartenbach, and CSO William Decker, PhD. Dr. Decker, an Associate Professor at Baylor College of Medicine, provides the foundational scientific expertise, while Mr. Hartenbach brings a blend of scientific knowledge and entrepreneurial experience from previous ventures in biotech and wellness. The company operates in the immuno-oncology market, developing personalized cancer vaccines for patients with late-stage cancers.

The company's core technology is a patient-derived dendritic cell vaccine, with its lead candidate named Dubodencel (DOC1021). This therapy's distinct feature is a proprietary "double-loading" technique that combines a patient's own tumor lysate (proteins) and amplified tumor-derived mRNA into their dendritic cells. This process is designed to mimic a viral infection, triggering a powerful and comprehensive TH1 immune response that targets the full spectrum of the patient's cancer antigens. A key benefit of this approach is that it avoids the need for genetic modification of immune cells or toxic preconditioning, offering a potentially safer treatment profile. The vaccine is administered through a series of injections into deep cervical lymph nodes, a method intended to generate a faster and more robust immune response.

Diakonos is advancing DOC1021 through multiple clinical trials. The therapy has received FDA Fast Track designation for treating glioblastoma (GBM) and pancreatic cancer, as well as Orphan Drug Designation for the GBM program. The company completed enrollment for its Phase I trial for glioblastoma in late 2023 and is proceeding with a Phase II trial. Clinical trials are also underway for pancreatic cancer and angiosarcoma. To fund these developments, Diakonos has secured significant financing, including an $11.4 million seed round and a subsequent $20 million SAFE financing, backed by investors such as the Restem Group, Baylor College of Medicine, and the Brain Tumor Investment Fund.

Source: Dealroom company data

At a glance

Status
Operational
Employees
24
Open positions
None listed
Dealroom signal
45.0/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Oncology, Immunotherapy, Biotech and Pharma, DT and LS
Business model
Manufacturing
Client focus
B2B

Funding history

3 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
GRANT✓Other financing Dec 2025 $7M — Cancer Prevention and Research Institute of Texas (CPRIT) ↗
EARLY VC✓Equity / VC May 2025 $20M $80M Baylor College of Medicine · Brain Tumor Investment Fund · Mike Wicks ↗
Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Diakonos Oncology website traffic

Latest recorded traffic for Diakonos Oncology is 2.8K monthly website visits, up 3.7% over the last three months.

Latest monthly visits2.8K 3-month web change+3.7%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Diakonos Oncology in the Houston ecosystem

Live from Dealroom

The Diakonos Oncology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

5 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed2 investors entered at this stage

  • Restem
  • Cancer Prevention and Research Institute of Texas (CPRIT)

Series A3 investors entered at this stage

  • Baylor College of Medicine
  • Brain Tumor Investment Fund
  • Mike Wicks
Team profiled 3 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇺🇸 United States94.4%
🇨🇦 Canada5.6%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Diakonos Oncology on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Diakonos Oncology’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.